Article

Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial

Medicine, Indiana University Melvin and Bren Simon Cancer Center.
Clinical Cancer Research (Impact Factor: 8.19). 01/2013; 19(5). DOI: 10.1158/1078-0432.CCR-12-3029
Source: PubMed

ABSTRACT Purpose Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA SNPs and overall survival (OS) in E2100. The associations between tumor VEGFA amplification and outcome are evaluated here. Patients and Methods E2100 was a phase III trial comparing paclitaxel with or without bevacizumab for patients with metastatic breast cancer. Fluorescence in situ hybridization to assess gene amplification status for VEGFA was performed on paraffin embedded tumors from 363 patients in E2100. Evaluation for association between amplification status and outcomes was performed. Results ER+ or PR+ tumors were less likely to have VEGFA amplification compared with ER/PR- tumors (p=0.020). VEGFA amplification was associated with worse OS (20.2 vs. 25.3 months; p=0.013) in univariate analysis with a trend for worse OS in multivariate analysis (p=0.08). There was a significant interaction between VEGFA amplification, hormone-receptor status, and study arm. Patients with VEGFA amplification and triple negative breast cancers (TNBCs) or HER2 amplification had inferior OS (p=0.047); amplification did not affect OS for those who were ER+ or PR+ and HER2-. Those who received bevacizumab with VEGFA amplification had inferior PFS (p=0.010) and OS (p=0.042); no association was seen in the control arm. Test for interaction between study arm and VEGFA amplification with OS was not significant. Conclusion VEGFA amplification in univariate analysis was associated with poor outcomes; this was particularly prominent in HER2+ or TNBCs. Additional studies are necessary to confirm the trend for poor OS seen on multivariate analysis for patients treated with bevacizumab.

Download full-text

Full-text

Available from: Guanglong Jiang, Jan 01, 2015
0 Followers
 · 
149 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor-related angiogenesis is a complex process resulting from a delicate balance between pro and anti-angiogenic factors. Bevacizumab, a fully humanized monoclonal antibody against vascular endothelial growth factor (VEGF), was the first anti-angiogenic therapy to prove effective, in combination with chemotherapy, for treatment of several types of advanced cancer, non-small-cell lung cancer (NSCLC) included. However, as for other types of solid malignancy, no predictive biomarkers of increased sensitivity to bevacizumab or any other anti-angiogenic drugs could be identified in NSCLC, which has had a negative affect on the cost-effectiveness of the targeted therapy performed to block the VEGF pathway. In this review we discuss the most relevant findings from clinical and correlative studies investigating the use of anti-angiogenic therapy for advanced NSCLC, focusing on the need to identify biomarkers for selection of patients suitable for anti-angiogenic therapy.
    06/2013; 2(2). DOI:10.1007/s13665-013-0046-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to evaluate the association of vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a phase II trial. This study evaluated weekly docetaxel, as first-line treatment for metastatic breast cancer. Existing data from in vitro and animal model experiments suggest that docetaxel at low doses has anti-angiogenic activity. DNA was extracted from blood samples of 86 patients participating in the trial. Genotyping was performed for selected single-nucleotide polymorphisms (SNPs; VEGF-2578, -1498, -1154, and +936). Moreover, due to the highly polymorphic nature of the studied areas, we were able to analyze additional registered SNPs. All candidate genotypes were evaluated for associations with overall survival (OS), progression-free survival (PFS) and response rate. The VEGF-1154 GG genotype was more frequent in patients not responding to treatment compared with responders (42.9% vs 0.0%, P=0.048). Moreover, the VEGF-2578 AA genotype was associated with longer PFS compared with CC (hazard ratio (HR)=0.40; 95% confidence interval (CI) 0.17-0.98; pairwise P=0.0457). Patients with the VEGF-1190 GG genotype demonstrated shorter PFS compared with those with the alternative genotypes (GA and AA) combined (HR=3.85; 95% CI: 1.20-12.50; P=0.0224). In addition, the VEGF-2551/-2534 homozygous del18bp and VEGF-2430/-2425 homozygous ins1bp genotypes were associated with worse PFS compared with no deletion and no insertion, respectively (HR=2.49; 95% CI: 1.02-6.07; pairwise P=0.0442 and HR=2.57; 95% CI: 1.05-6.27; pairwise P=0.0385, respectively). Furthermore, patients with the VEGF-1498 CC genotype exhibited longer median OS compared with those with the alternatives genotypes (CT and TT) combined (HR=0.27; 95% CI: 0.08-0.89; P=0.0311). In multivariate analysis, the VEGF-2578 AA genotype retained its significance (P=0.0220) for PFS. Our results support the association of specific VEGF genotypes with clinical outcome in patients with metastatic breast cancer treated with a potentially anti-angiogenic regimen, such as weekly docetaxel. However, current results should be validated prospectively in larger cohorts.The Pharmacogenomics Journal advance online publication, 24 September 2013; doi:10.1038/tpj.2013.36.
    The Pharmacogenomics Journal 09/2013; DOI:10.1038/tpj.2013.36 · 5.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim: Pharmacogenetic studies in breast cancer (BC) may predict the efficacy of tamoxifen and the toxicity of paclitaxel and capecitabine. We determined the frequency of polymorphisms in the CYP2D6 gene associated with activation of tamoxifen, and those of the genes CYP2C8, CYP3A5 and DPYD associated with toxicity of paclitaxel and capecitabine. We also included a IL-10 gene polymorphism associated with advanced tumor stage at diagnosis. Patients & methods: Genomic DNAs from 241 BC patients from northeast Mexico were genotyped using DNA microarray technology. Results: For tamoxifen processing, CYP2D6 genotyping predicted that 90.8% of patients were normal metabolizers, 4.2% ultrarapid, 2.1% intermediate and 2.9% poor metabolizers. For paclitaxel and the CYP2C8 gene, 75.3% were normal, 23.4% intermediate and 1.3% poor metabolizers. Regarding the DPYD gene, only one patient was a poor metabolizer. For the IL-10 gene, 47.1% were poor metabolizers. Conclusion: These results contribute valuable information towards personalizing BC chemotherapy in Mexican women. Original submitted 1 February 2013; revision submitted 22 April 2013.
    Pharmacogenomics 10/2013; 14(13):1583-1592. DOI:10.2217/pgs.13.83 · 3.43 Impact Factor